Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

07-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint

print
PRINT
insite
SEARCH

David McDermott talks through his renal cell carcinoma research exploring the use of a novel oral CXCR4 inhibitor and treatment-free survival as an alternative endpoint for immunotherapy trials (4:03).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript here


This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits